KNSA - Kiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call Transcript

2024-04-23 13:59:07 ET

Kiniksa Pharmaceuticals Ltd. (KNSA)

Q1 2024 Earnings Conference Call

April 23, 2024 8:30 AM ET

Company Participants

Rachel Frank - Associate Director of Investor Relations

Sanj Patel - Chief Executive Officer

Ross Moat - Senior Vice President & Chief Commercial Officer

John Paolini - Senior Vice President & Chief Medical Officer

Mark Ragosa - Senior Vice President & Chief Financial Officer

Eben Tessari - Chief Operating Officer

Conference Call Participants

Anupam Rama - JP Morgan

Paul Choi - Goldman Sachs

David Nierengarten - Wedbush Securities

Geoff Meacham - Bank of America

Presentation

Operator

Good day and thank you for standing by and welcome to Kiniksa Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. After the speakers’ presentation there will be a question and answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Rachel Frank, Head of Investor Relations. Please go ahead.

Rachel Frank

Thank you, operator. Good morning, everyone and thank you for joining Kiniksa's call to discuss our first quarter 2024 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the Investors section.

As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with the introduction. Ross Moat, our Chief Commercial Officer will provide an update on our ARCALYST commercial execution. John Paolini, our Chief Medical Officer, will provide the abiprubart program review, then Mark Ragosa, our Chief Financial Officer will review our first quarter 2024 financial results. And finally, Sanj will return for closing remarks and to kick off the Q&A session, for which Eben Tessari, our Chief Operating Officer will also be on the line.

Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption Risk Factors contained in our SEC filings. These statements speak only as of the date of this presentation and we undertake no obligation to update such statements, except as required by law....

For further details see: